Skip to main navigation

Ernst &Young Services AABS RAS FIDS Fraud Investigation and Dispute Services - Ernst & Young - United States

Fraud Investigation & Dispute Services

Our Fraud Investigation & Dispute professionals can help you address the challenges and risks of doing business in today's environment.

We help companies find ways to manage risk, investigate alleged misconduct, and measure the financial implications of disputes. With experience across multiple industries, Ernst & Young has the global reach that today's companies need.

We investigate unusual financial activity, perform electronic evidence discovery, and review financial reports — all with the sensitivity and urgency you require. And we provide expert witness testimony as necessary to explain our findings. That’s why some of the world’s largest companies — and many of its best-known law firms — turn to Ernst & Young.

Read some of the success stories from Ernst & Young member firms around the world.

Our services include:

Fraud and investigations
Dispute services
Forensic technology and discovery services
Anti-fraud services
Corporate compliance
Insurance claims services 
Environment and sustainability
Government contract services

Detecting financial statement fraud

Given the current state of the economy, falling energy prices and recent corporate scandals, fraud is still a top concern for corporate executives. Every organization is vulnerable to fraud, and managers must know how to (pdf, 209K)  detect it — or at least when to suspect it.

FIDS authors new AICPA fraud book

On September 4, the AICPA published "The Guide to Investigating Business Fraud", written by the Fraud Investigation & Dispute Services practice. It's a first-of-its-kind, complete guide that looks at the principles and techniques of investigating fraud. It is a must read for forensic accountants, litigation attorneys, corporate boards and management, audit committees and accounting students. You can learn more about the book and order your copy here.

Pharma pricing and promotion activities

Drug pricing and marketing practices are coming under ever more regulatory scrutiny. US and non-US companies should be on their guard. This article addresses the (pdf, 92K) current issues and risks related to drug pricing statutes, off-label promotion, gift-giving, clinical trials and more.

A done deal – except when it isn’t

One-third of all closed transactions end with a dispute between the parties. That already high percentage is likely to increase given the uncertainty about valuations and the general tightness in the debt markets. This article explains how (pdf, 42K) post-deal dispute risks can be mitigated with forethought and planning.

Ernst & Young Online

Learn more
Learn more

Return to Login

 
Back to top